Buy & Sell Honeywell International Inc (HON) – Honeywell International Inc Price Today
Aura AI Summary
Key Stats
- $146.83BMarket Cap
- IndustrialsSector
- -15.72%3M Drawdown
- $171.18BEnterprise Value
- 2.05%Dividend Yield
- 10% Buy | 90% SellTrading Activity
- 84 daysTypical Hold Time
Honeywell International Inc (HON) is currently valued at a market capitalization of $146.83B, with an enterprise value of $171.18B. Over the past 52 weeks, Honeywell International Inc has traded between a low of $188.14 and a high of $248.04, highlighting its annual price range. Over the past three months, Honeywell International Inc has recorded a drawdown of -15.72%, reflecting recent price volatility. Honeywell International Inc offers a dividend yield of 2.05%, with the most recent dividend of $1.19 paid on 15 May 26. On average, investors hold Honeywell International Inc for approximately 84 days, indicating typical investor behavior on the platform.
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
